Atrion CorporationAtrion Corporation Investor Relations
Home

  
 Print   View All
Nov 09, 2020
Atrion Reports Third Quarter Results

ALLEN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced that for the third quarter ended September 30, 2020 revenues totaled $33.8 million compared with $38.9 million for the same period in 2019. Net income for the third quarter of 2020 totaled $7.2 million as compared to $9.6 million for the same period in 2019, with diluted earnings per share for the third quarter of 2020 at $3.95 compared to $5.15 for the third quarter of 2019.

Commenting on the Company's quarterly results for the third quarter of 2020 compared to the same period last year, David A. Battat, President & CEO, stated, "Our results for the quarter were disappointing, with revenues down 13%, operating income down 27% and diluted EPS down 23%. In the second quarter of this year, our revenues began to weaken as our hospital and OEM customers reported a significant slowdown in surgeries due to the need for Covid-19 beds in hotspots, as well as continued patient reluctance to schedule surgeries. This trend accelerated in the third quarter, and we expect similar weakness in the fourth quarter of this year. Our customers are reporting that these declines in procedures are deferred rather than never to be performed, and, therefore, they expect to see a gradual recovery in 2021 as patients can no longer delay the need for care and hospitals adapt to expand their surgical capacity."

Mr. Battat continued, "We never make excuses for subpar results, but we remain optimistic. Despite the negative comparisons, the Company remains profitable and debt-free, while holding cash and short and long investments totaling $88.2 million as of September 30, 2020."

Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com.

Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially.  Such statements include, but are not limited to, Atrion's expectations regarding the demand for our products in the fourth quarter of 2020 and an increase in procedures in 2021. Words such as "expects," "believes," "anticipates," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements.  Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.

Contact: Jeffery Strickland
  Vice President and Chief Financial Officer
  (972) 390-9800
   


 
ATRION CORPORATION
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
    
 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 2020 2019 2020 2019
Revenues$33,785  $38,883  $115,348  $120,600 
Cost of goods sold 18,887   20,992   63,114   65,414 
Gross profit 14,898   17,891   52,234   55,186 
Operating expenses 7,315   7,441   22,891   22,732 
Operating income 7,583   10,450   29,343   32,454 
        
Interest and dividend income 303   733    1,161    1,896 
Other investment income (loss)  678    (106)   5    265 
Income before income taxes 8,564   11,077   30,509   34,615 
Income tax provision (1,321)  (1,482)  (5,764)  (5,918)
Net income $7,243  $9,595  $24,745  $28,697 
        
Income per basic share$3.96  $5.17  $13.46  $15.48 
        
Weighted average basic shares outstanding 1,829   1,855   1,839   1,854 
        
        
Income per diluted share$3.95  $5.15  $13.42  $15.40 
        
Weighted average diluted shares outstanding 1,834   1,862   1,844   1,863 
                


 
ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
    
 Sep 30, Dec 31,
ASSETS2020
 2019
 (Unaudited)  
Current assets:   
Cash and cash equivalents$23,996  $45,048 
Short-term investments 18,779   23,766 
Total cash and short-term investments 42,775   68,814 
Accounts receivable 17,747   18,886 
Inventories 48,622   42,093 
Prepaid expenses and other 4,013   2,545 
Total current assets 113,157   132,338 


Long-term investments
 45,381   31,772 


Property, plant and equipment, net
 91,053   84,606 
Other assets 13,441   13,315 
    
 $263,032  $262,031 
    
    
LIABILITIES AND STOCKHOLDERS' EQUITY   
    
Current liabilities 12,699   11,274 
Line of credit --   -- 
Other non-current liabilities 12,215   12,887 
Stockholders' equity 238,118    237,870 
    
 $263,032  $262,031 
        

Primary Logo